Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
March 07 2024 - 4:18PM
Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or
the “Company”), an integrated contract development and
manufacturing organization (CDMO), today announced that it intends
to offer to sell shares of its common stock to the public in an
underwritten public offering. All of the shares of common stock are
to be sold by the Company.
ThinkEquity is acting as sole book-running
manager for the offering.
The Company intends to use the net proceeds from
the offering primarily for working capital and general corporate
purposes.
The securities will be offered and sold pursuant
to a shelf registration statement on Form S-3 (File No.
333-251255), including a base prospectus, filed with the U.S.
Securities and Exchange Commission (the “SEC”) on December 10, 2020
and declared effective on December 22, 2020. The offering will be
made only by means of a written prospectus. A preliminary
prospectus supplement and the accompanying base prospectus
describing the terms of the offering will be filed with the SEC on
its website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying base prospectus relating to the
offering may also be obtained from the offices of ThinkEquity, 17
State Street, 41st Floor, New York, New York 10004. Before
investing in this offering, interested parties should read in their
entirety the preliminary prospectus supplement and the accompanying
base prospectus and the other documents that the Company has filed
with the SEC that are incorporated by reference into such
preliminary prospectus supplement and the accompanying base
prospectus, which provide more information about the Company and
such offering
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
state or jurisdiction.
About Scorpius Holdings,
Inc.
Scorpius Holdings Inc. is an integrated large
molecule contract development and manufacturing organization (CDMO)
focused on rapidly advancing biologic and cell therapy programs to
the clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions and include statements
regarding the timing and completion of the proposed offering.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
ability to complete the proposed offering and other factors
described in the Company’s annual report on Form 10-K for the year
ended December 31, 2022, subsequent quarterly reports on Form 10-Qs
and any other filings the Company makes with the SEC. The
information in this presentation is provided only as of the date
presented, and the Company undertakes no obligation to update any
forward-looking statements contained in this press release on
account of new information, future events, or otherwise, except as
required by law.
For Investor Relations
Inquiries:
David Waldman
+1 919 289 4017
investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2023 to Apr 2024